EIM
CDTX

Essex Investment Management’s Cidara Therapeutics CDTX Stock Holding History

Essex Investment Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-646
Closed -$67K – 409
2018
Q2 		$67K Buy
+646
New +$61K 0.01% 390

Other funds holding CDTX

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Essex Investment Management's CDTX Position: Q3 2018 in Review

Essex Investment Management sold out of Cidara Therapeutics (CDTX) in Q3 2018, closing a stake of 646 shares — an estimated $67K sold.

Essex Investment Management first reported a position in CDTX in Q2 2018 and held it in 1 quarter. The position peaked at $67K in Q2 2018. 59 funds tracked by Wall St. Rank hold CDTX as of Q3 2018.

  • Essex Investment Management reported no remaining Cidara Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Essex Investment Management sold 646 Cidara Therapeutics shares in Q3 2018, an estimated $67K.
  • Essex Investment Management first reported a position in Cidara Therapeutics in Q2 2018 and held it in 1 quarter.
  • Essex Investment Management's Cidara Therapeutics position peaked at $67K in Q2 2018.
  • 59 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2018.

Based on Essex Investment Management's 13F filing for Q3 2018, filed 16 Oct 2018.